摘要
目的 探讨血清腓骨蛋白1(fibulin-1,FBLN-1)在卵巢癌患者中的表达水平及临床诊断意义。方法 选取2023年7月至2024年6月就诊于连云港市立东方医院经手术病理确诊的卵巢癌患者83例(卵巢癌组),卵巢良性肿瘤患者70例(良性组),以及同期接受体检的健康女性90例(对照组)。应用酶联免疫吸附实验(ELISA)和化学发光法分别测定各组血清FBLN-1、糖类抗原125(CA125)、人附睾蛋白4(HE4)水平。绘制受试者工作特征(ROC)曲线分析FBLN-1、CA125、HE4单独及联合检测对于卵巢癌的诊断效果。结果 卵巢癌组的血清FBLN-1水平[(30.51±6.12)ng/mL]较卵巢良性肿瘤组[(12.85±5.55)ng/mL]和健康对照组[(16.09±5.62)ng/mL]显著升高(P<0.001)。Ⅲ期、Ⅳ期组卵巢癌组患者血清FBLN-1、CA125、HE4水平显著高于Ⅰ期和Ⅱ期组患者(P<0.001)。FBLN-1、CA125和HE4联合检测诊断卵巢癌的ROC曲线下面积(AUC)为0.917,高于FBLN-1(0.879)、CA125(0.790)、HE4(0.826)。结论 血清FBLN-1水平在卵巢癌患者中显著升高,且随卵巢癌进展水平升高,与CA125、HE4联合检测对卵巢癌具有较高辅助诊断潜力。
Objective To investigate the expression level of serum fibulin-1(FBLN-1)in ovarian cancer and evaluate its clinical diagnostic significance.Methods Between July 2023 and June 2024,83 ovarian cancer patients confirmed by postoperative pathology(ovarian cancer group),70 patients with benign ovarian tumors(benign group),and 90 healthy women undergoing routine health examinations(control group)were enrolled at Lianyungang Municipal Dongfang Hospital.Serum levels of FBLN-1,cancer antigen 125(CA125),and human epididymis protein 4(HE4)were measured using enzyme-linked immunosorbent assay(ELISA)and chemiluminescence methods.Receiver operating characteristic(ROC)curve analysis was performed to assess the diagnostic performance of FBLN-1,CA125,and HE4 individually as well as in combination.Results The ovarian cancer group exhibited significantly higher serum FBLN-1 levels[(30.51±6.12)ng/mL]compared to the benign group[(12.85±5.55)ng/mL]and the control group[(16.09±5.62)ng/mL](P<0.001).In addition,patients with stageⅢandⅣovarian cancer had significantly higher serum levels of FBLN-1,CA125,and HE4 than those with stageⅠandⅡdisease(P<0.001).The combined detection of FBLN-1,CA125,and HE4 yielded an area under the ROC curve(AUC)of 0.917,which was superior to the AUC for FBLN-1(0.879),CA125(0.790),and HE4(0.826)when used alone.Conclusion Serum FBLN-1 levels are significantly elevated in ovarian cancer patients and correlate with disease progression.The combined measurement of FBLN-1,CA125,and HE4 demonstrates high potential as an auxiliary diagnostic tool for ovarian cancer.
作者
王永琪
薄维波
陈守庆
陈霞
WANG Yong-qi;BO Wei-bo;CHEN Shou-qing;CHEN Xia(Department of Laboratory Medicine,Lianyungang Municipal Dongfang Hospital,Lianyungang 222042,Jiangsu,China;不详)
出处
《广东医学》
2025年第4期611-614,共4页
Guangdong Medical Journal
基金
连云港市卫生科技项目指导性课题(ZD202305)。
